Rhesus-Inkompatibilität in der Schwangerschaft

Prophylaxe mit Anti-D-Immunglobulinen
Dr. med. Georg Wittmann, Prof. Dr. med. Michael Spannagl & Prof. Dr. med. Reinhard Henschler

  1. Tiblad E, Taune Wikman A, Ajne G, Blanck A, Jansson Y, Karlsson A, Nordlander E, Holländer BS, Westgren M. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation-outcome of a new antenatal screening and prevention program. PLoS One 2013 Aug 6; 8(8):e70984.
  2. Wikman AT, Tiblad E, Karlsson A, Olsson ML, Westgren M, Reilly M. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012 Aug; 120(2 Pt 1):227-234.
  3. Kümper C. Rheusprophylaxe in A. Strauss: Geburtshilfe Basics; Springer Medizin Verlag Heidelberg 2006, Seite 334, ISBN-13: 978-3540256687.
  4. Bombard AT, Akolekar R, Farkas DH, Van Agtmael AL, Aquino F, Oeth P, Nicolaides KH. Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women. Prenat Diagn 2011 Aug; 31(8):802-808.
  5. Gebrauchs- und Fachinformation Octapharma: rhesonativ®; Stand September 2013
  6. Gebrauchs- und Fachinformation CSL Behring: Rhophylac 300®; Stand Februar 2013
  7. Royal College of Obstetricians and Gynaecologists, RCOG Green-top Guideline No. 22 March 2011, The Use of Anti-D Immunoglobulin for Rhesus D Prophylaxis; Date published: 27/04/2011 (http://www.rcog.org.uk/womens-health/clinical-guidance/use-anti-d-immunoglobulin-rh-prophylaxis-green-top-22). 
  8. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Zweite Richtlinienanpassung 2010; Bundesanzeiger ISSN 0720-6100 G1990, Jahrgang 62 Nummer 101a vom 9. Juli 2010:1-40.
  9. Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über die ärztliche Betreuung während der Schwangerschaft und nach der Entbindung („Mutterschafts-Richtlinien“) in der Fassung vom 10. Dezember 1985 (veröffentlicht im Bundesanzeiger Nr. 60a vom 27. März 1986); zuletzt geändert am 21. März 2013, veröffentlicht im Bundesanzeiger AT vom 29. Mai 2013 B5 vom 1. Juli 2013: www.kbv.de/39319.html.
  10. Wagner FF, Kasulke D, Kerowgan M, Flegel WA. Frequencies of the blood groups ABO, Rhesus, D category VI, Kell, and of clinically relevant high-frequency antigens in south-western Germany. Infusionsther Transfusionsmed. 1995 Oct; 22(5):285-90.
  11. Flegel WA. The Rhesus-Site: www.uni-ulm.de/~wflegel/RH.
  12. Flegel WA. Denomme GA. Allo- and autoanti-D in weak D types and in partial D. Transfusion 2012 Sep; 52(9):2067-2069.

    gyne-Gespräch: Deszensus-Operation

    Wie gerechtfertigt ist der Einsatz von Netzenb
    Petra Peschel
    Seiten 16-19

    1. Klingler HC, Dietersdorfer F, Dörfler C, Fink KG, Fischer M, Heidler H, Madersbacher H, Petrovic Z, Pferschy J, Pitzler C, Primus G, Schrey A, Stoces U, Wachter J. Descensus urogenitalis der Frau: Positionspapier des Arbeitskreises für Blasenfunktionsstörungen der ÖGU zur interdisziplinären AWMF-Leitlinie 015/006. J Urol Urogynäkol 2011; 18(2):27-32.
    2. www.awmf.org/leitlinien/detail/ll/015-006.html
    3. Bader W, Bässler K, Dimpfl T, Hagemeier T, Kölbl H, Petri E, Reisenauer C. Stellungnahme der Arbeitsgemeinschaft für Urogynäkologie und plastische Beckenbodenrekonstruktion (AGUB) für die Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG): Stellungnahme zur FDA-Sicherheitswarnung betreffend Verwendung von alloplastischem Material im Rahmen der Deszensuschirurgie; Berlin, August 2011.
    4. www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm262435.htm
    5. Maher et al. Cochrane Data base 2010, Issue 4. Art. No: CD 004014.
    6. Baessler K. Do we need meshes in pelvic floor reconstruction? World J Urol 2012; 30:479–486; DOI 10.1007/s00345-011-0794-9.
    7. Petri E, Kölbl H (Hrsg.). Gynäkologische Urologie: Interdisziplinäre Diagnostik und Therapie, 4. vollständig überarbeitete Auflage; Thieme Verlag Stuttgart 2013. ISBN 978-3-13-639104-4.
    8. American Urogynecologic Society (AUGS) 33rd Annual Scientific Meeting. Paper Presentation 30. Presented Oct 5, 2012.
    9. Pullen LC. Vaginal mesh removal difficult and may not relieve pain. Medscape. Oct 09, 2012.
    10. Altman D, Väyrynen T, Engh ME, Axelsen S, Falconer C; Nordic Transvaginal Mesh Group. Anterior colporrhaphy versus transvaginal mesh for pelvic-organ prolapse. N Engl J Med. 2011 May 12; 364(19):1826-1836. Doi: 10.1056/NEJMoa1009521.
    11. Maher C, Feiner B, DeCuyper EM, Nichlos C, Hickey K, O’Rourke P. Laparoscopic sacral colpopexy versus total vaginal mesh for vaginal vault prolapse. A randomized trial. Am J Obstet Gynecol. 2011; 204 (4):360.e1-360.e7.
    12. Maher C, Feiner B, Baessler K, Schmid C. Surgical management of pelvic organ prolapse in women. Cochrane Database Syst Rev. 2013 Apr 30; 4:CD004014. Doi: 10.1002/14651858.CD004014.pub5.
    13. Maher C, Baessler K, Glazener CM, Adams EJ, Hagen S. Surgical management of pelvic organ prolapse in women. Cochrane Database Syst Rev. 2007 Jul 18; (3):CD004014.

      Hormonale Kontrazeption: Blutungsstörungen (Teil 4)

      Management bei dem Hormonimplantat, Kontrazeptionspflaster und Levonorgestrel-Intrauterinsystem
      Gemeinsame Stellungnahme der DGGEF e.V. und des BVF e.V. (Prof. Dr. med. Dr. med. h.c. Thomas Rabe federführend) und des Arbeitskreises „Blutungsstörungen bei der Frau“
      Seiten 20-25

      1. Mansour D, Korver T, Marintcheva-Petrova M and Fraser IS. The effects of Implanon on menstrual bleeding patterns Europ J Contracept and Reproduc Health Care 2008; 13:13-28.
      2. Mansour D, Fraser IS, Walling M, Glenn D, Graesslin O, Egarter C, Herbst J. Methods of accurate localisation of non-palpable subdermal contraceptive implants. J Fam Plann Reprod Health Care 2008; 34:9-12.
      3. Mansour D, Walling M, Glenn D, Egarter C, Graesslin O, Herbst J, Fraser IS Removal of nonpalpable etonogestrel implants. J Fam Plann Reprod Health Care 2008; 34:89-91.
      4. Mansour D, Mommers E, Teede H, Sollie-Eriksen B, Graesslin O, Ahrendt HJ, Gemzell-Danielsson K. Clinician satisfaction and insertion characteristics of a new applicator to insert radiopaque Implanon: an open-label, noncontrolled, multicenter trial. Contraception 2010; 82: 243–249.
      5. Olsson SE, Odlind V, Johansson E. Clinical results with subcutaneous implants containing 3-keto-desogestrel. Contraception 1990 Vol. 42 No. 1:1-11.
      6. Cullberg G, Lindtstedt G, Lundberg G, Lundberg PA, Steffensen K. Central and peripheral effects of desogestrel 15–60 ?g daily for 21 days in healthy female volunteers. Acta Obstet Gynecol Scand 1982, Suppl 111:21–8.
      7. Graesslin O, Korver T. The contraceptive efficacy of Implanon®: A review of clinical trials and marketing experience. European Journal of Contraception and Reproductive Health Care, Volume 13, Supplement 1, June 2008; 9:4-12.
      8. Weisberg E, Hickey M, Palmer D, Connor VO, Salamonson LA, Findlay JK and Fraser IS. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009; 24:1852-1861.
      9. Ahrendt HJ, Egarter C. Blutungsstörungen unter reiner Gestagen-Langzeit-Kontrazeption mit subdermalen Implantaten, Teil 2 Management von Zusatzblutungen unter subdermalen Implantaten. Frauenarzt 2011;5:493-501.
      10. Belsey EM. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988; 38:181–206.
      11. Collaborative Study Group on the Desogestrel-Containing Progestogen-Only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 1998; 3: 169–178.
      12. Mansour D, Korver T, Marintcheva-Petrova M and Fraser IS. The effects of Implanon on menstrual bleeding patterns Europ J Contracept and Reproduc Health Care 2008; 13:13-28.
      13. Edwards JE, Moore A. Implanon: A review of clinical studies. Br J Fam Plann 1999; 24(4suppl):3-16.
      14. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception 1998; 58 (suppl): 99–107.
      15. Zheng SR, Zheng HM, Qian SZ et al. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 1999; 60:1–8.
      16. Livingston M, Fraser IS. Mechanismen of abnormal uterine bleeding. Human Reprod Update 2002; 8:60-67.
      17. Hickey M, d’Arcangues C. Vaginal bleeding disturbances and implantable contraceptives
      18. Contraception 2002;65:75–84. Mansour D, Korver T, Marintcheva-Petrova M and Fraser IS. The effects of Implanon on menstrual bleeding patterns Europ J Contracept and Reproduc Health Care 2008; 13:13-28.
      19. Vincent AJ, Salamonsen LA. The role of matrix metalloproteinases and leucocytes in abnormal uterinebleeding associated with progestin-only contraceptives. Hum Reprod 2000; 15:135-143.
      20. Ahrendt HJ, Egarter C. Blutungsstörungen unter reiner Gestagen-Langzeit-Kontrazeption mit subdermalen Implantaten, Teil 2 Management von Zusatzblutungen unter subdermalen Implantaten. Frauenarzt 2011; 5:493-501.
      21. Weisberg E, Hickey M, Palmer D et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006; 21:295-302.
      22. Weisberg E, Hickey M, Palmer D, Connor VO, Salamonson LA, Findlay JK and Fraser IS. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009; 24:1852-1861.
      23. Ahrendt HJ, Egarter C. Blutungsstörungen unter reiner Gestagen-Langzeitkontrazeption mit subdermalen Implantaten, Teil 1: Menstruation und Zusatzblutungen und seine beeinflussenden Faktoren. Frauenarzt 2011; 4:376-382.
      24. Weisberg E, Hickey M, Palmer D et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006; 21:295-330.
      25. Weisberg E, Hickey M, Palmer D, Connor VO, Salamonson LA, Findlay JK and Fraser IS. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009; 24:1852-1861.
      26. Abdel-Aleem H, d’Arcangues C, Vogelsong KK, Gülmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin only contraceptives. (Review) Cochrane 2009.
      27. Ahrendt HJ, Egarter C. Blutungsstörungen unter reiner Gestagen-Langzeitkontrazeption mit subdermalen Implantaten, Teil 2: Management von Zusatzblutungen unter subdermalen Implantaten. Frauenarzt 2011; 5: 493-501.
      28. www.rxlist.com/ortho_evra-drug.htm
      29. Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2000; 98:799-805.
      30. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, Creasy GW. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch versus an oral contraceptive: a randomized controlled trial. JAMA 2001; 285:2347-2354.
      31. Urdl W, Apter D, Alperstein A, Koll P, Schonian S, Bringer J, Fisher AC, Preik M. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Eur J Obstet Gynecol Reprod Biol 2005; 121:202-210.
      32. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 microg versus > 20 microg estrogen combined oral contraceptives for contraception. Cochrane Database Syst 2011; Rev:CD003989.
      33. Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol 2005; 18:85-90.
      34. Römer T, Linsberger D. User satisfaction with a levonorgestrel-releasing intrauterine system (LNGIUS): data from an international survey. Eur J Contracept Reprod Health Care 2009; 14:391-398.
      35. Luukkainen T. Levonorgestrel-Releasing Intrauterine Device. Annals of the New York Academy of Sciences 1991; 626:43–49.
      36. Sholten PC.The Levonorgestrel IUD; Clinical performance and impact on menstruation, Thesis University Utrecht; 1987.
      37. Jensen JT et al. Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception 2008; 77:22-29.
      38. Endrikat J, Vilos G, Muysers C, Fortier M, Solomayer E, Lukkari-Lax E. The levonorgestrelreleasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia. Arch Gynecol Obstet 2012; 285 (1):117-121. 
      39. Shabaan MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 2011; 83:48-54.
      40. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164:879-88.
      41. Lethaby AE, Cooke I, Rees M. Progesterone or progestagen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005: 19:CD002126.
      42. Middleton LJ, Champaneria R, Daniels JP, Bhattacharya S, Cooper KG, Hilken NH, O´Donovan P, Gannon M, Gray R, Khan KS. Hysterectomy, endometrial destruction, an levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients. BMJ 2010; 341: c3929.
      43. Lethaby AE, Cooke I, Rees M. Progesterone or progestagen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005: 19:CD002126.
      44. Römer T. Erfahrungen und Empfehlungen zur Anwendung des Levonorgestrel Intrauterinsystems. Thieme Praxis Report 2009; 1:1-24.
      45. Vilos GA, Marks J, Tureanu V, Abu-Rafea B, Vilos AG. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol 2011; 18:75-80.
      46. Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril 2008; 90:673-677.
      47. Fachinformation: MIRENA® Intrauterinpessar mit Hormonabgabe; Juli 2010.
      48. Römer T. MIRENA® - Eine besondere Form der hormonellen Kontrazeption. Frauenheilkunde update 2011; 5(3): 177-193. DOI: 10.1055/s-0031-1271533.
      49. Gemzell-Danielsson K, Inki P, Boubli L, O´Flynn M, Kunz M, Heikinheimo O. Bleeding pattern and safety of consecutive use of the levonorgestrelreleasing intrauterine system (LNG-IUS) – a multicentre prospective study. Hum Reprod 2010; 25:354-359.
      50. Römer T. Erfahrungen und Empfehlungen zur Anwendung des Levonorgestrel Intrauterinsystems. Thieme Praxis Report 2009; 1:1-24.

        CME Fortbildung: Zervikale intraepitheliale Neoplasie

        Prävention, Diagnostik und Therapie
        PD Dr. med Julia Gallwas & PD Dr. med Christian Dannecker
        Seiten 26-30

        1. World Health Organization (WHO). Incidence, mortality and survival database. 2002; Link: www.who.int/cancer/
        2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011 Mar-Apr;61(2):69-90.
        3. Krebs in Deutschland 2007/2008. Häufigkeiten und Trends. 8. Ausgabe. Berlin 2012; Robert-Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg).
        4. Bose CK. Cancer screening for women in developing countries. Nature 2009;4:459(7247):641.
        5. WHO/ICO Information centre on HPV and cervical cancer (HPV information center): Human papilloma virus and related cancer in Germany. Summary report 2009; World Health Organization 2009.
        6. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW. ASCCP Consensus Guidelines Conference 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013 Apr;121(4):829-846.
        7. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Iftner T. Inclusion of HPV-testing in routine cervical cancer screening for women above 29 years in Germany: Results for 8.466 patients. Br J Cancer 2003 May 19;88(10):1570-1577.
        8. Kahn JA. HPV-Vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med 2009;361(3):271.
        9. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005 Apr;6(4):204.
        10. Castellsague X, Bosch FX, Munoz N. Environmental co-factors in HPV carcinogenesis. Virus Res 2002;89:191-199.
        11. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003 Feb 6;348(6):518-527.
        12. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004 Jun;68(2):362-372.
        13. Durst M, Glitz D, Schneider A, zur Hausen H. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: Analysis by in situ hybridization. Virology 1992 Jul;189(1):132-140.
        14. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004;78:11451-11460.
        15. Laudadio J. Human papillomavirus detection: Testing methodologies and their clinical utility in cervical cancer screening. Adv Anat Pathol 2013 May;20(3):158-167. 
        16. Castle PE, de Sanjosé S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 2012 Nov 20;30 Suppl 5:F117-122. 
        17. Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz AT, J L M Meijer C, Sankaranarayanan R, J F Snijders P, Szarewski A. New technologies and procedures for cervical cancer screening. Vaccine 2012 Nov 20;30 Suppl 5:F107-116.
        18. Ostor A. Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 1993;12(2):186-192.
        19. Arends MJ, Buckley CH, Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J.Clin.Pathol 1998;51:96-103.
        20. Dunton CJ. Management of atypical glandular cells and adenocarcinoma in situ. Obstet Gynecol Clin North Am 2008;35(4):623-632.
        21. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, Miller S, Canjura-Clayton KL, Farhat S, Broering JM, Darragh TM. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004;364(9446):1678.
        22. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med 2000 May16;132(10):810-819. 
        23. Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: A systematic review and meta-analysis. Syst Rev 2013 May 24;2:35.
        24. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, Ghiringhello B, Giorgi-Rossi P, Minucci D, Parisio F, Pojer A, Schiboni ML, Sintoni C, Zorzi M, Segnan N, Confortini M. Accuracy of liquid based versus conventional cytology: Overall results of new technologies for cervical cancer screening: Randomised controlled trial. BMJ 2007;335(7609):28.
        25. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: A systematic review and meta-analysis. Obstet Gynecol 2008;111(1):167.
        26. Nobbenhuis MA, Meijer CJ, van den Brule AJ, Rozendaal L, Voorhorst FJ,  Risse EK, Verheijen RH, Helmerhorst TJ. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84:796-801.
        27. Wright TC Jr, Massad S, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197(4):346-355.
        28. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studieson HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101.
        29. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, Cohen C. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-362.
        30. Shafi MI, Petry U, Bosch XF, Gissman L, Kocken M, Helmerhorst TJ, Stanley M, Nazeer S, European Federation for Colposcopy. European consensus statement on "HPV-Vaccination and Colposcopy". J Low Genit Tract Dis 2011 Oct;15(4):309-315.
        31. Nazeer S, Shafi MI. Objective perspective in colposcopy. Best Pract Res Clin Obstet Gynaecol 2011 Oct;25(5):631-640.
        32. Hallam NF, West J, Harper C, Edwards A, Hope S, Merriman H, Pandher KS, Pinches P, Slade R, Marsh G. Large loop excision of the transformation zone (LLETZ) as an alternative to both local ablative and cone biopsy treatment: A series of 1.000 patients. J Gynecol Surg 1993;9(2):77.
        33. Petry KU, Glaubitz M, Maschek H, Böhmer G, Linge G, Kühnle H. Die elektrochirurgische Schlingenexzision der Transformationszone (LEEP) zur Behandlung zervikaler Neoplasien. Geburtshilfe Frauenheilkd 1996;56:513-516.
        34. Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO, Keep SL. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2010 Jun 16;(6):CD001318.
        35. Oyesanya OA, Amerasinghe C, Manning EA. A comparison between loop diathermy conization and cold-knife conization for management of cervical dysplasia associated with unsatisfactory colposcopy. Gynecol Oncol 1993;50(1):84.
        36. Soergel P, Jentschke M, Hillemanns P. Zervikale intraepitheliale Neoplasie 3. Gynäkologe 2012;45:276-280.
        37. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR et  al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol 2005 May;6(5):271-278.
        38. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006 Nov;118(5):2135-2145.
        39. Robert-Koch-Institut. Mitteilung der Ständigen Impfkommission (STIKO) am Robert- Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren. Empfehlung und Begründung. Epidemiologisches Bulletin 12; 2007.
        40. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 May 10;356(19):1928-1943.
        41. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM et al. Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Followup from a randomised control trial. Lancet 2006 Apr 15;367(9518):1247-1255.
        42. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence inpatients with high-grade cervical intraepithelial neoplasia (CIN 2-3)? Gynecol Oncol 2013 Aug;130(2):264-268.

        Ulipristalazetat als selektiver Progesteron-Rezeptormodulator

        Aktueller Stand zum Einsatz in der Notfallkontrazeption
        Dr. med. Julia Bartley, PD Dr. med. Andreas Schüring & PD Dr. med. Sören von Otte Seiten 34-38

        1. Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo. ClinicalTrials.gov Identifier: NCT01569113. clinicaltrials.gov/ct2/show/study/NCT01569113
        2. Baird DD, McConnaughey DR, Weinberg CR, Musey PI, Collins DC, Kesner JS, Knecht EA, Wilcox AJ. Application of a method for estimating day of ovulation using urinary estrogen and progesterone metabolites. Epidemiology 1995; 6: 547-550.
        3. Brache V, Cochon L, Jesam C, Maldonado R, Salvatierra AM, Levy DP, Gainer E, Croxatto HB. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Human Reprod 2010; 25:2256-2263.
        4. Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: Analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 2013; 88: 611-618.
        5. Cameron S, Gemzell-Danielsson K, Klipping C, Michie L, Berger C, Levy D, Abitbol JL. Ulipristal acetate (UPA) versus levonorgestrel (LNG) and quick start of contraception. First Global Conference on Contraception, Reproductive and Sexual Health, 22. To 25.05.2013;  Kopenhagen; Abstract book: ESA03-2, S.45.
        6. Croxatto HB, Brache V, Pavez M, Cochon L, Forcelledo ML, Alvarez F, Massai R, Faundes A, Salvatierra AM. Pituitary-ovarien function following the standard levonorgestrel emergency contraceptive dose or a single 0,75 mg dose given on the days preceding ovulation. Contraception 2004; 70: 442-450.
        7. David M, Radke AM, Pietzner K. Die Verordnung der sog. Pille danach in einer Berliner Kliniknotfallambulanz in einem 4-Jahres-Zeitraum: Anwenderinnenprofil und Anwendungsgründe. Geburtsh Frauenheilk 2012; 72:392-396.
        8. Faculty of Sexual and Reproductive Health, Clinical Effectiveness Unit, Emergency Contraception: www.fsrh.org/pdfs/CEUstatementEsmya.pdf.
        9. Gemzell-Danielsson K, Berger C, Lalitkumar PGL. Emergency contraception – mechanism of action. Contraception 2013a; 87:300-308.
        10. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol. Endocrinol 2013b; 29:1-14.
        11. Glasier AF, Cameron ST, Fine PM, Logan SJS, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. The Lancet 2010; 375:555-562.
        12. Glasier A. Clinical update on ulipristal acetate (ellaOne®) emergency contraception. Orally lecture on the HRA symposium. SS04.3. First global conference of the ESC on contraception, reproductive and sexual health in Kopenhagen (Dänemark); 2013, 22. bis 25. Mai.
        13. Gould JE, Overstreet JW, Hanson FW. Assessment of human sperm function after recovery from the female reproductive tract. Biol. Reprod 1984; 31:888-894.
        14. Micevych P, Sinchak K. Estradiol regulation of progesterone synthesis in the brain. Mol. Cell Endocrinol 2008; 290:44-50.
        15. Munuce MJ, Zumoffen C, Cicaré J, Caille A, Ghersevich S, Bahamondes L. Effect of exposure to ulipristal acetate on sperm function. Eur J Contracept Reproduct Health Care 2012; 17:428-437.
        16. Massai MR, Forcelledo ML, Brache V, Tejada AS, Salvatierra AM, Reyes MV, Alvarez F, Faúndes A, Croxatto HB. Does meloxicam increase the incidence of anovulation induced by single administration levonorgestrel in emergency contraception? A pilot study. Human Reproduct 2007; 22:434-439.
        17. Nallasamy S, Kim J, Sitruk-Ware R, Bagchi M, Bagchi I. Ulipristal blocks ovulation by inhibiting progesterone receptor-dependent pathways intrinsic to the ovary. Reproduct Sci 2013 Apr; 20(4):371-381.
        18. Nappi RE. What do women know about pregnancy risk and emergency contraception? A European survey amongst 7170 women. Orally lecture on the HRA symposium. 10. Congress of the European Society of Gynecology; Brüssel (Belgien), 18. to 21. September 2013.
        19. Noé G, Croxatto HB, Salvatierra AM et al. Contraeptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception 2011; 84: 486-492.
        20. Palanisamy GS, Cheon YP, Kim J, Kannan A, Li Q, Sato M, Mantena SR, Sitruk-Ware RL, Bagchi MK, Bagchi IC. A novel pathway involving progesterone receptor endothelin-2, and endothelin receptor B controls ovulation in mice. Mol. Endocrinol 2006; 20:2784-2795.
        21. Rabe T, Albring C. Notfallkontrazeption: ein Update. Gemeinsamen Stellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin (DGGEF) e.V. und des Berufsverbands der Frauenärzte (BVF) e.V.; Update vom 6.2.2013. Frauenarzt 2013; 54:108-114.
        22. Rabe T, Albring C. Checkliste für die Verordnung von Notfallkontrazeption im ärztlichen Bereitschaftsdienst. Frauenarzt 2013; 54, Beilage.
        23. Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004; 25:45-71.
        24. Stratton P, Hartog B, Hajizadeh N, Piquion J, Sutherland D, Merino M, Lee YJ, Nieman LK. A single mid-follicular dose of CDB-2914, a new antiprogestin inhibitis folliculugenesis  and endometrial differentiation in normally cycling women. Human Reproduct 2000; 15:1092–1099.
        25. Wilcox AJ, Dunson D, Baird DD. The timing of the fertile window in the menstrual cycle: day specific estimates from a prospective study. BMJ 2000; 321:1259–1262.
        26. Yeung WSB, Chiu PC, Wang CH, Yao YQ, Ho PC. The effects of levonorgestrel on various sperm functions. Contraception 2002; 66:453–457.
        27. Zalányi S. Progesterone and ovulation. Europ J Obstet Gynecol Reprod Biol 2001;98: 152–159